| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biology and Volen Center for Complex Systems, Brandeis University, Waltham, Massachusetts
Submitted 1 March 2005; accepted in final form 8 May 2005
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
55%, whereas 5-HT inhibition is weaker (35%). The half-maximal inhibitory concentration of both 5-HT and NE is 1 µM. Neither NE nor 5-HT affected paired-pulse facilitation, suggesting that the effect is not presynaptic. This is in contrast to DA, which does have a presynaptic effect. The NE effect was blocked by 
2 antagonists, whereas the 1 antagonist corynanthine and 
-antagonist propranolol were ineffective. The effect of 5-HT was mimicked by the agonist, 5-carboxamidotryptamine maleate (5-CT), and not affected by adrenergic and dopaminergic antagonists. To determine the 5-HT receptors involved, we tested a number of 5-HT antagonists, but none produced a complete suppression of the 5-HT effect. Of these, only the 5-HT7 and 5-HT2 antagonists produced weak but significant inhibition of 5-HT effect. We conclude that NE inhibits the PP fEPSP through postsynaptic action on 2-adrenoceptors and that 5-HT7, 5-HT2, and some other receptor may be involved in 5-HT action in PP. |
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
). DA axons arrive from all three major midbrain sources (Gasbarri et al. 1989, 1991, 1996); NE axons come from the locus coeruleus (Lopes da Silva et al. 1990; Swanson et al. 1987); and 5-HT axons come from the dorsal raphe nuclei, unlike other hippocampal regions that are innervated by the median raphe nucleus (Azmitia and Segal 1978; Barnes and Sharp 1999; Lopes da Silva et al. 1990; Morin and Meyer-Bernstein 1999; Swanson et al. 1987). Monoamines can affect both the excitability of CA1 cells and their synaptic plasticity. For instance, NE, DA, and 5-HT increase the excitability of pyramidal cells through , D1, and 5-HT4 receptors, all of which are positively coupled to cAMP-dependent mechanisms (Andrade 1998; Madison and Nicoll 1986; Malenka and Nicoll 1986; Pedarzani and Storm 1995). On the other hand, 5-HT2 receptors decrease their excitability (Andrade 1998). Inhibitory interneurons are excited by -adrenergic (Bergles et al. 1996) and 5-HT3 serotonergic action (McMahon and Kauer 1997; Shen and Andrade 1998). DA and NE may also affect activity-dependent synaptic plasticity, facilitating long-term potentiation (LTP) (Frey et al. 1993; Huang and Kandel 1995; Katsuki et al. 1997; Otmakhova and Lisman 1996; Otmakhova et al. 2000; Swanson-Park et al. 1999; Thomas et al. 1996) and inhibiting depotentiation in the CA3
CA1 synapses (Otmakhova and Lisman 1998). Both effects seem to be mediated by cAMP-dependent mechanisms.
Recent work points to a third type of action of monoamines in CA1, the modulation of synaptic conductances (Otmakhova and Lisman 1999, 2000). Monoamines strongly suppress the baseline synaptic transmission of the perforant path (PP) input that comes directly from cortex. The other major input to CA1 comes from CA3 through the Schaffer collaterals (SC) and is much less strongly affected by all three monoamines. The PP is important for hippocampal function because it is the main source of specific sensory information for the CA1 region (McNaughton et al. 1989; Vinogradova 1984, 2001). A heightened level of the PP activity is required for performance of learned behavior in monkeys (Sybirska et al. 2000). Furthermore, selective inhibition of the PP input to CA1 may interfere with the "comparator function" of CA1 in which novelty is computed based on a comparison of PP and SC inputs. Therefore abnormalities in the monoamine system could potentially underlie the deficits in hippocampal novelty detection that have been implicated in schizophrenia (Gray 1998; Lisman and Otmakhova 2001). We have already described in detail dopaminergic action in the PP (Otmakhova and Lisman 1999). The goal of this paper is to characterize the 5-HT and NE effects. In particular we sought to determine whether the site of action is pre- or postsynaptic and to analyze the receptor subtypes involved.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
) were placed in the CA1 hippocampal region, closer to the subiculum than to CA3 (Fig. 1A). Two electrodes were placed in the distal one-third of the stratum radiatum 150–200 µm apart from each other for stimulating and recording from the SC synapses. Another pair of similar electrodes was positioned in the stratum lacunosum-moleculare to stimulate and record from the PP synapses. The distance between the PP electrodes was 100 µm. The region of CA1 adjoining the subiculum is a site of mostly lateral PP projections (Lopes da Silva et al. 1990; Swanson et al. 1987). More than 90% of those form excitatory axo-spinous synapses (Desmond et al. 1994). There are also inputs from the nucleus reuniens of the thalamus in s. lacunosum-moleculare, but 50% of those axons contact inhibitory interneurons (Desmond et al. 1994; Dolleman-Van Der Weel and Witter 1996). Following previous researchers and to simplify the description, we term these inputs the PP input. Data acquisition and initial on-line analysis were done using a PC through a Digidata 1200 interface (Axon Instruments, Foster City, CA) using a custom-made AXOBASIC program. We alternated the stimulation between PP and SC inputs; each input was stimulated every 20 s.
|
, 1999; Otmakhova et al. 2000). Previously performed model experiments with methylene blue (50 µM) (Otmakhova and Lisman 1996) showed that the dye reached the recording chamber within 12–15 s after the start of the perfusion and was washed out within 1.5–2.5 min after dye flow was switched off.
For statistical analysis, responses were collected and averaged in 1- and 5-min periods. The amplitudes (mV) of the fEPSP and the fiber volley were measured. Data were normalized relative to baseline. The effects of drugs on the baseline were estimated in each slice relative to baseline and analyzed for the whole experimental series using two-tailed paired t-test for means (Microsoft Excel). Concentration–response curve fitting was done in Microcal ORIGIN. Antagonist potency was estimated by comparing the monoamine effect in the presence or absence of the antagonist on the same slices because within-slice comparison is more sensitive at detecting drug effects than between-slice comparison (Otmakhova and Lisman 1998). The whole 25-min period of application and washout was analyzed in two-factor ANOVA for repeated measurements, followed by posthoc paired t-test for each 5-min interval (Microsoft Excel). Considered factors were drug (presence or absence of the antagonist; df = 1), time (since the start of amine application in 5-min bins, df = 4), and drug x time interaction (df = 4). As a standard requirement, an a priori value of 0.05 was established before all experiments. Figures show means and SE.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
). Indeed, because the effects on the SC were minor, we will restrict our description to the PP pathway. NE and 5-HT effects on the PP fEPSP
In this study as before (Otmakhova and Lisman 2000), application of 5-HT (20 µM, n = 13) and NE (20 µM, n = 9; Fig. 1, B and C) caused a suppression of the PP fEPSP. The effect was evident in the first 1–2 min of application and reached a maximum by 5 min (Fig. 1C). The reversal of this effect followed a similar time-course (Fig. 1C) and was on average 5 min slower than the reversal of the DA effect (Otmakhova and Lisman 1999, 2000). Neither monoamine affected the fiber volley, the indicator of axonal excitability. At 20 µM concentration, the NE-induced suppression was consistently stronger than suppression caused by 5-HT (Fig. 1, B and C). It should be noted that the action of 5-HT was the most variable of the three monoamines.
To investigate the concentration-dependence of the 5-HT and NE effects in PP (Fig. 1, D and E), monoamines were applied to the slice at five different concentrations (0.5, 1, 5, 20, and 100 µM), and the maximal fEPSP amplitude suppression was measured (between 10 and 15 min of application). Monoamine was applied for 15 min with a 30-min period of washout between applications. No more than three applications of different concentrations were used per slice. After averaging (n = 4–9 for each concentration), concentration–response curves were fitted on logarithmic scale (with SE as weights). The 5-HT effect saturated at 35.9 ± 1.3%. Half-maximal inhibition (IC50) occurred at 0.98 ± 0.03 µM. The maximal inhibition for NE was much stronger (–55.5 ± 3.9%; Fig. 1, C and F), but the IC50 was similar to 5-HT (1.2 ± 0.25 µM). Compared with DA-induced inhibition of the PP fEPSP (45 ± 2%) (Otmakhova and Lisman 1999), the maximal effect of NE was the largest, whereas that of 5-HT was the smallest of the three monoamines (Fig. 1G). However, the half-maximal inhibition was achieved by a smaller concentration of NE and 5-HT compared with DA (3 µM; Fig. 1F).
Monoamines are easily oxidized in solutions; we were concerned that oxidation products might be responsible for the effect in slices. To control for this, 5-HT (10 µM, n = 4) and NE (10 µM, n = 3) were applied in the presence of a very high concentration of antioxidant, ascorbic acid (400 µM). The inhibition of the PP fEPSP observed in these experiments (46.7 ± 2.6 and 58.2 ± 3.4%, respectively) was in the upper range of the distribution of the response in regular ACSF, indicating that the effect is not mediated by breakdown products of 5-HT or NE.
Site of the action of NE and 5-HT
The best current input-specific test of presynaptic localization of a substance’s effect is the change in probability of release as monitored by the speed of irreversible NMDA blockade during synaptic stimulation (Hessler et al. 1993). However, this test is flawed if the tested substance can affect the behavior of NMDA channels. This is known to happen for NE (Raman et al. 1996) and 5-HT (Arvanov et al. 1999). A simpler and more widely used test that generally reflects presynaptic action and allows input-specific testing is paired-pulse facilitation (PPF). Under our experimental conditions (1.3 mM Mg2+ in ACSF), this test should be largely NMDA-independent, although other postsynaptic effects cannot be excluded and care should be taken with interpretation of results. We previously concluded on the basis of PPF changes that DA-induced suppression of the PP fEPSP was at least partially presynaptic (Otmakhova and Lisman 1999). Here we tested whether it was the same for 5-HT and NE effects. The PPF experiments were performed in the presence of picrotoxin (50 µM) to avoid the interference of GABAA inhibition. Stimuli were applied every 30 s in pairs of pulses with an interpulse delay of 50 ms. 5-HT (10 µM) or NE (10 µM) were perfused for 10 min after 15 min of stable baseline to insure the maximal suppression of the PP fEPSP. To control for the possible effect of decreased fEPSP amplitude on the PPF, the power of stimulation was increased to return fEPSP amplitude to the baseline level. Pairs of the increased fEPSP were recorded for an additional 5 min. PPF was calculated during baseline, monoamine application, and increased stimulation using the following formula: PPF = 100% x second/first.
Figure 2 compares the effect of 5-HT and NE of PPF with previously obtained DA data (Otmakhova and Lisman 1999). It shows that the decrease in the PP fEPSP amplitude by 5-HT or NE was not associated with significant changes in PPF (Fig. 2). For 5-HT, PPF was 141.5 ± 5% in control, 151.4 ± 5.1% during application, and 149.7 ± 6.7% during a stronger stimulation period (P > 0.15, n = 7). For NE, it was 140.6 ± 11.2, 136 ± 10.1, and 127.4 ± 5.8%, respectively (P > 0.2, n = 6; Fig. 2). To compare, PPF increase by DA was highly significant: 140.2 ± 2, 170.3 ± 4, and 163.4 ± 6% (P < 0.01, n = 6). Therefore a presynaptic site of action for 5-HT or NE appears unlikely.
|
To study the receptors mediating 5-HT and NE action, we used the experimental design shown efficient in the study of DA (Otmakhova and Lisman 1999). NE was always applied at 10 µM. In each slice, we first applied the NE alone (control) for 15 min. After 30–40 min of washout, we applied the antagonist and later NE again in the presence of antagonist. The effects of two applications (Fig. 3) were compared using two-factor ANOVA. This comparison was valid because we ascertained that repeated NE application produced reproducible effects (P > 0.5, n = 4).
|
). Specifically, 1-adrenoceptors are coupled through Gq/11 to phospholipase activation and internal Ca2+ stores. 2 type is coupled to Gi/o protein with the possibility to inhibit adenylyl cyclase or activate K+ channels through 
subunits. -adrenoceptors mostly activate adenylyl cyclase through Gs protein. To test for the involvement of -adrenergic receptors, we used the selective antagonist propranolol (1 µM). This antagonist did not inhibit the NE action (F = 1.3, P > 0.3, n = 5, Fig. 3A). Similarly, the 1-specific antagonist, corynanthine (5 µM), was without effect (F = 0.26, P > 0.6, n = 6, Fig. 3B). However, the 2 antagonist yohimbine (5 µM) strongly (75%) inhibited the effect of NE (F = 49.5, P < 0.001, n = 4). We checked whether another 2-antagonist would completely block NE action in PP. We found that efaroxan hydrochloride at 10 µM concentration completely blocked the NE effect in PP (F = 169.2, P < 0.001, n = 5; Fig. 3D). Therefore the NE-induced suppression of the PP fEPSP is probably mediated through 2-adrenoreceptors. Receptors involved in 5-HT action in PP
Our previous experiments (Otmakhova and Lisman 2000) showed that clozapine inhibited the 5-HT effect on the PP fEPSP by 26.2 ± 1.7%. Clozapine is not a selective drug; aside from dopaminergic, adrenergic, and muscarinic receptors (Jackson and Mohell 1996), clozapine has been shown to inhibit multiple 5-HT receptors: 5-ht6, 5-HT7 (Hedlund et al. 1999; Larkman and Kelly 1997; Thomas et al. 1998), 5-HT2A, 5-HT2C, 5-HT1A, and 5-HT1D (Jackson and Mohell 1996; Richelson and Souder 2000). Therefore we had to test multiple 5-HT receptors one by one. In all these experiments, 5-HT was applied at saturating 10 µM concentration. Because there were too many possibilities to check, in most cases we used only one concentration of antagonist. This was chosen in the upper range of doses shown to be effective in published experiments. We used this strategy because it worked well in DA and NE experiments before; however, its value may be decreased if some of the antagonists are not very specific or are partial agonists on same or other receptors. As with DA and NE, 5-HT was initially applied alone, and then after 30–40 min of washout, 5-HT was applied to the same slice in the presence of the antagonist. As with other monoamines, there was no change in the 5-HT effect with repeated applications 30–40 min apart (P > 0.55, n = 8).
Because the most abundant 5-HT receptor in CA1 region is GI/O-coupled 5-HT1A receptor (Kia et al. 1996; Swanson et al. 1987; Wright et al. 1995), we started by examining the effect of the selective 5-HT1A-receptor antagonist, WAY 100635. The reported effective doses of this drug were unusually low (nM) but we tested it at several concentrations (10 nM, 100 nM, 500 nM, and 1 µM). It was ineffective at all concentrations (F = 2.5, P > 0.2, n = 4). We also checked whether the selective antagonist of the 5-HT1B receptor GR 55662 (5 µM) inhibited the action of 5-HT. The result was also negative (F = 3.2, P > 0.09, n = 4; Table 1).
|
). Ketanserin inhibited the effect of 5-HT weakly (17 ± 4.3%) but significantly (F = 6.9, P < 0.02, n = 4; Table 1). These results suggest that some subtype of 5-HT2 receptors might participate in the 5-HT effect, but in a minor way. The 5-HT3 antagonist tropisetron (30 µM) unexpectedly had an effect on its own: it significantly increased the baseline synaptic response (by 18.4 ± 2.3%, P < 0.01). The baseline usually stabilized in first 10 min of antagonist application and did not change after that. Although tropisetron may also work on 5-HT4 receptors, this effect is probably not attributable to 5-HT4 antagonistic action because a more selective 5-HT4 antagonist did not have this effect. However, partial agonistic action on 5-HT4 receptors may be involved in this effect. What is more important, tropisetron had no effect on 5-HT–induced suppression of the PP fEPSP (F = 0.07, P > 0.7, n = 4; Table 1).
As a test for the role of 5-HT4 receptors, we tried 5-HT4–selective antagonist SDZ 205–557. Paradoxically, SDZ 205–557 (10 µM) significantly increased the effect of 5-HT (26.2 ± 4%; F = 11.4, P < 0.002, n = 4; Table 1). SDZ 205–557 is also active against 5-HT3 receptor (30 times lower affinity). However, because we did not observe any effects of more selective 5-HT3 antagonist tropisetron, the SDZ 205–557 effects were probably 5-HT4–dependent. This suggests that normally 5-HT4 receptor inhibits the 5-HT action on the PP.
There were no selective antagonists for 5-HT5 receptors available. Therefore we could not investigate these receptors directly. 5-HT6 receptors could be a functionally attractive target because of their sensitivity to neuroleptics, antidepressants, and LSD (Branchek and Blackburn 2000). We have tested a 5-HT6 antagonist, SB-258585 (5 µM). There were no significant effects of this antagonist on either baseline or 5-HT–induced suppression of PP fEPSP (F = 3.4, P > 0.07, n = 6, Table 1). However, this was not surprising because 5-HT6 receptor immunoreactivity was shown to be concentrated in stratum oriens and s. radiatum of CA1 region, not in s. lacunosum-moleculare (Gerard et al. 1997). To check on 5-HT7 receptor action, we used the 5-HT7-selective antagonist SB-269970 (5 µM). SB-269970 significantly inhibited the 5-HT–induced suppression of PP fEPSP (F = 4.78, P < 0.04, n = 5; Table 1). The average effect of SB-269970 was quite strong (37% inhibition); however, there was a large dispersion of data between slices, ranging from 100% to 5% inhibition of 5-HT action. These results suggest that 5-HT7 receptor participates in 5-HT action, but that some additional receptor is also involved.
Because only two antagonists (5-HT2 and 5-HT7) showed significant inhibition of serotonin effect in PP, we decided to check whether their combined effect would be more substantial. Before the second 5-HT application, we applied the combination of ketanserin and SB-269970 (5 µM each). The effect of combined antagonist on the second 5-HT application was significant (F = 17.1, P < 0.001, n = 6) but not larger than the effects of each antagonist alone: the 5-HT effect in PP was inhibited by only 15% (Table 1).
There remained the possibility of nonspecific action of 5-HT on DA and NE receptors. DA strongly inhibits the PP input acting through D1 and D2 type of receptors (Otmakhova and Lisman 1999) and, as established above, NE inhibits the PP through the 2 type of receptors. If 5-HT inhibits the PP by acting on DA or NE receptors then the antagonists of D1, D2, or 2 type of receptors should block its action. We performed experiments to check these possibilities. Applying 5-HT in the presence of a mixture of D1 antagonist SCH 23390 (5 µM) and D2 antagonist eticlopride (5 µM) did not inhibit the 5-HT effect (F = 3.37, P > 0.08, n = 4; Table 1). Therefore 5-HT evidently does not act through DA receptors.
To check whether 5-HT might act through NE receptors we applied the 2 antagonist, yohimbine (5 µM). However, yohimbine only weakly inhibited the serotonin action (14.4 ± 4.8%; F = 4.77, P < 0.04, n = 4; Table 1). This result suggested that 5-HT could not act primarily through 2-adrenoceptors, because NE effect was almost completely blocked by yohimbine (Fig. 3C). The small effect we see need not necessarily be due to 2-adrenoceptors because yohimbine is also known to block some 5-HT2 receptors (Marcoli et al. 1997; Sanden et al. 2000). We also studied whether -adrenergic receptors might participate in 5-HT action, using the -adrenergic antagonist, propranolol (1 µM). This drug did not affect the NE action, but we considered a test prudent because propranolol is also known to antagonize 5-HT1 type of receptors. Propranolol did not affect the 5-HT–induced suppression of the PP synaptic input (F = 3.2, P < 0.09, n = 5). Therefore the 5-HT effect on the PP was not mediated by the nonspecific action on -adrenergic receptors. This experiment also provides an additional confirmation that 5-HT in PP did not act through 5-HT1–dependent mechanism (Table 1).
As a final test of the specificity of 5-HT action in PP, we investigated whether it might be mimicked by 5-HT agonist, 5-CT. 5-CT is an effective agonist for 5-HT1, 5-HT2B, 5-HT5, 5-HT6, and 5-HT7 receptors (Alexander and Peters 1999; Hoyer et al. 1994; Kebabian and Neumeyer 1994). To each slice (n = 6), we first applied 5-HT (10 µM) and then 5-CT (0.3 µM) for 15 min each with 40-min washout between applications. The results were compared in two-factor ANOVA. We found that 5-CT strongly inhibited the PP fEPSP (P < 0.001) to slightly higher degree than 5-HT, although this tendency did not reach significance (P < 0.09, 2-tailed). The washout of 5-CT was slower than 5-HT (Fig. 4). These results together with previous data indicate that 5-HT action was indeed 5-HT receptor-specific.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
; Dvorak-Carbone and Schuman 1999; Remondes and Schuman 2002, 2004), it is important to understand the mechanisms that modulate this input. Previous work has shown that the PP fEPSPs are strongly reduced by the three monoamines, DA, NA, and 5-HT (Fig. 1), whereas the SC inputs are nearly unaffected (Otmakhova and Lisman 2000). It has been unclear whether these monoamine effects have similar sites of action. Interestingly, the results revealed a profound difference from previously obtained DA data. DA appeared to acts at least partially through inhibition of presynaptic release of glutamate as was indicated by a significant increase in PPF (Otmakhova and Lisman 1999). In contrast, neither NE nor 5-HT affected PPF (Fig. 2), suggesting a postsynaptic site of action.
We have also characterized the receptors involved in serotonergic and adrenergic action, complementing the previous work on dopamine (Otmakhova and Lisman 1999). We have found that NE suppresses the PP fEPSP through 2-specific action. The effect was almost completely blocked by the 2-antagonists, but was not affected by either 1 or by antagonists (Fig. 3). The concentration of adrenergic fibers (Oleskevich et al. 1989) and -adrenoceptors (Swanson et al. 1987) in CA1 s. lacunosum-moleculare has long been recognized. More recent publications show that it is the 2 type (and 2C subtype) of -adrenoceptors that is localized to this region both in rodent (Dossin et al. 2000; Holmberg et al. 2003) and in human brain (Gonzalez et al. 1994; Pazos et al. 1985). Therefore our conclusion is consistent with histological data on 2 receptor localization.
Our extensive efforts to characterize the receptors mediating 5-HT action strongly restricted the range of possibilities but still did not yield a complete picture. We were never able to completely inhibit the effect of 5-HT, the strongest inhibition being 37%. The partially effective antagonists implicate 5-HT7 and 5-HT2 receptors (Table 1). Consistent with this, histological data suggest that 5-HT2 (Swanson et al. 1987) and 5-HT7 receptors (Neumaier et al. 2001) might be selectively enriched in s. lacunosum-moleculare compared with other CA1 layers, which would explain our physiological effects. However, the lack of complete blockade of 5-HT effect by 5-HT7 and 5-HT2 antagonists and even by clozapine (the antagonist for multiple 5-HT receptors) suggests a more complicated picture of 5-HT targets in the PP.
One possibility is that the 5-HT effect depends mostly on the receptors known to be present in the hippocampus but for which we do not yet have effective antagonists (like 5-HT1F or 5-HT5B). The immunostaining for 5-HT5B receptors appears relatively high in s. lacunosum-moleculare (Oliver et al. 2000). These receptors are still pharmacologically inaccessible since no selective ligands are commercially available. A new group of trace amine receptors (TAR) with a high homology to serotonin receptors has been recently described. TAR may also be activated by 5-HT, DA, and NE and, when expressed, couple to GS protein and cAMP synthesis (Berry 2004; Borowsky et al. 2001; Bunzow et al. 2001). The details of TAR localization are not yet available, but the trace amines (agonists of TAR) are present in the hippocampus (Berry 2004).
It might also be that we observed some form of cooperation between two or more serotonin receptor subtypes, where each subtype inhibition alone does not have substantial effect, and two or more receptors should be inhibited simultaneously. A clustering (heterodimerization) of different subtypes of G protein–coupled receptors was recently described (Franco et al. 2000; George et al. 2000; Hebert and Bouvier 1998; Rocheville et al. 2000a,b) but the full functional significance of such dimerization is not yet known. It might be that the striking similarity of the distribution of 5-HT7 and 5-HT5B protein in the hippocampus and relatively high level of both in the s. lacunosum-moleculare (Brownfield et al. 1998) indicates a possible interaction of these two receptors in the control over PP synaptic transmission. This might be a cause for variability of the effect of 5-HT7 antagonist, SB-269970. It appears even more reasonable because 5-CT (and, of cause, 5-HT) activates both 5-HT7 and 5-HT5 receptors while SB-269970 (and clozapine) do not inhibit the 5-HT5 type (Table 1). Another possibility is the interaction between 5-HT7 and 5-HT1 receptors as described for ventral pallidum (Bengtson et al. 2004). In this particular case, 5-HT effect was mimicked by 5-HT1/5-HT7 agonists and was not blocked by either 5-HT7 or 5-HT1 antagonist alone. This last work is of particular interest, because in this case, 5-HT acted through hyperpolarization-activated nonselective cationic channels (Ih channels) through cAMP-dependent mechanisms (Bengtson et al. 2004). We have recently shown a strong Ih-dependence of the PP EPSP (Otmakhova and Lisman 2004) according to which increase in the resting Ih current might cause the decrease in EPSP size. It will therefore be of interest to determine whether 5-HT (and other monoamines) suppression of PP EPSP may be mediated by Ih current. Studies to understand the mechanisms underlying monoamine modulation are now needed, and we have begun such efforts in our laboratory.
Functional significance of monoaminergic control of the PP
NE and 5-HT participate in control of mood and mood disorders—aggression (Chiavegatto et al. 2001; Gurvits et al. 2000; Kavoussi et al. 1997; Maj et al. 2000; Oquendo and Mann 2000), depression, stress, and anxiety (Brody et al. 1999; Grahn et al. 1999; Lopez et al. 1999; Mayberg et al. 2000; Svensson 2000). NE, especially its 2 receptors are important in the maintenance of selective attention and the decrease of distractibility (Coull 1994). Hippocampal NE and 5-HT turnover is increased by stress in mice (Belzung et al. 2001), consistent with a role in such behaviors. However, the main focus of research on hippocampal NE has been on its release during novelty signal and its affect on hippocampal excitability (Kitchigina et al. 1997).
NE and 5-HT also play some role in schizophrenic psychotogenesis (Syvalahti 1994; Carlsson 1995; Elkashef et al. 1995; Oades et al. 1996; Frederick and Meador-Woodruff 1999). The increase in DA and NE levels by introduction of amphetamines could induce psychosis (Curran and Travill 1997; Laruelle and Abi-Dargham 1999; Yui et al. 1997). Amphetamine psychosis recurrence correlates with blood levels of NE and metabolites (Yui et al. 1997). The NE agonist ephedrine can produce hallucinations (Prokop 1968). NE contribution to the causes of psychosis is suggested by the therapeutic action of neuroleptic drugs having a potent -adrenoceptor binding abilities correlating with their clinical efficacy (Cohen et al. 1988). Similarly to NE and DA, substantial changes in serotonin function are associated with dramatic distortions in cognitive processes, including hallucinations. Specific examples include schizophrenia (Iqbal and van Praag 1995; Kapur and Remington 1996; Meltzer 1995), Lewy body dementia (Perry et al. 1990), delusional state of depression (Benedetti et al. 1999), indolamine hallucinations (Aghajanian and Marek 1999; Egan et al. 1998; Iqbal and van Praag 1995; Perry et al. 1990; Schifano et al. 1998).
Several lines of investigations suggest that the hippocampus might be a critical site for hallucinogenesis (Gloor 1997). Hallucinations were observed in cases of hippocampal dysfunction with glioma in the hippocampus (Kan et al. 1989), temporal lobe impairments in Alzheimer’s disease (Lopez et al. 2001), and in temporal lobe epilepsy (Conlon et al. 1990; Ferguson et al. 1969; Hyde and Weinberger 1997; Maier et al. 2000; Sachdev 1998; Stevens and Lonsbury-Martin 1985). The role of the hippocampus in auditory hallucinations has been shown in schizophrenic patients (Silbersweig et al. 1995; Woodruff et al. 1997). Some authors specifically stress the role of the CA1 region in epileptic psychosis (Suckling et al. 2000) noting that degree of psychosis paradoxically correlates with the degree of preservation of CA1; evidently the presence of the dysfunctional CA1 is required for psychosis. The CA1 controls the hippocampal output to the cortex and receives two cortical inputs—the PP and SC inputs. Interestingly, all hallucinogenic mechanisms (NMDA antagonism or increases in monoamine function) would specifically target the same CA1 input, the PP (Otmakhova and Lisman 1999, 2000; Otmakhova et al. 2002). A deeper understanding of receptor and ionic mechanisms controlling the PP may be helpful in the development of effective antipsychotic drugs.
|
GRANTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
Present address of J. Lewey: Harvard Medical School, Boston, MA 02115.
|
ACKNOWLEDGMENTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
|
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. E. Lisman, Volen CCS, Brandeis Univ., 415 South St., Waltham, MA 02454 (E-mail: lisman{at}brandeis.edu)
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONGRANTSACKNOWLEDGMENTSREFERENCES |
|---|
Alexander SPH and Peters JA (Editors). TiPS Receptor and Ion Channel Nomenclature Supplement. Trends Pharmacol Sci 19: 1–120, 1999.
Andrade R. Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Ann NY Acad Sci 861: 190–203, 1998.
Arvanov VL, Liang X, Magro P, Roberts R, and Wang RY. A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 11: 2917–2934, 1999.[CrossRef][ISI][Medline]
Azmitia EC and Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179: 641–667, 1978.[CrossRef][ISI][Medline]
Barnes NM and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083–1152, 1999.[CrossRef][ISI][Medline]
Belzung C, El Hage W, Moindrot N, and Griebel G. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 41: 400–408, 2001.[CrossRef][ISI][Medline]
Benedetti F, Zanardi R, Colombo C, and Smeraldi E. Worsening of delusional depression after sleep deprivation: case reports. J Psychiatr Res 33: 69–72, 1999.[CrossRef][ISI][Medline]
Bengtson CP, Lee DJ, and Osborne PB. Opposing electrophysiological actions of 5-HT on noncholinergic and cholinergic neurons in the rat ventral pallidum in vitro. J Neurophysiol 92: 433–443, 2004.
Bergles DE, Doze VA, Madison DV, and Smith SJ. Excitatory actions of norepinephrine on multiple classes of hippocampal CA1 interneurons. J Neurosci 16: 572–585, 1996.
Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 90: 257–271, 2004.[CrossRef][ISI][Medline]
Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, and Gerald C. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98: 8966–8971, 2001.
Branchek TA and Blackburn TP. 5-ht6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 40: 319–334, 2000.[Medline]
Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, and Baxter LR. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 91: 127–139, 1999.[CrossRef][ISI][Medline]
Brownfield MS, Yracheta J, Chu F, Lorenz D, and Diaz A. Functional chemical neuroanatomy of serotonergic neurons and their targets: antibody production and immunohistochemistry (IHC) for 5-HT, its precursor (5-HTP) and metabolite (5-HIAA), biosynthetic enzyme (TPH), transporter (SERT), and three receptors (5-HT2A, 5-ht5a, 5-HT7). Ann NY Acad Sci 861: 232–233, 1998.
Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, and Grandy DK. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181–1188, 2001.
Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol 10(Suppl 3): 21–28, 1995.
Chiavegatto S, Dawson VL, Mamounas LA, Koliatsos VE, Dawson TM, and Nelson RJ. Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. Proc Natl Acad Sci USA 98: 1277–1281, 2001.
Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dowling MS, and Pickar D. The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci 43: 1141–1150, 1988.[CrossRef][ISI][Medline]
Colbert CM and Levy WB. Long-term potentiation of perforant path synapses in hippocampal CA1 in vitro. Brain Res 606: 87–91, 1993.[CrossRef][ISI][Medline]
Conlon P, Trimble MR, and Rogers D. A study of epileptic psychosis using magnetic resonance imaging. Br J Psychiatry 156: 231–235, 1990.
Coull JT. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drugs Aging 5: 116–126, 1994.[ISI][Medline]
Curran HV and Travill RA. Mood and cognitive effects of +/–3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end 'high’ followed by mid-week low. Addiction 92: 821–831, 1997.[CrossRef][ISI][Medline]
Desmond NL, Scott CA, Jane JA Jr, and Levy WB. Ultrastructural identification of entorhinal cortical synapses in CA1 stratum lacunosum-moleculare of the rat. Hippocampus 4: 594–600, 1994.[CrossRef][ISI][Medline]
Dolleman-Van Der Weel MJ, and Witter MP. Projections from the nucleus reuniens thalami to the entorhinal cortex, hippocampal field CA1, and the subiculum in the rat arise from different populations of neurons. J Comp Neurol 364: 637–650, 1996.[CrossRef][ISI][Medline]
Dossin O, Mouledous L, Baudry X, Tafani JA, Mazarguil H, and Zajac JM. Characterization of a new radioiodinated probe for the alpha2C adrenoceptor in the mouse brain. Neurochem Int 36: 7–18, 2000.[CrossRef][ISI][Medline]
Dvorak-Carbone H and Schuman EM. Long-term depression of temporoammonic-CA1 hippocampal synaptic transmission. J Neurophysiol 81: 1036–1044, 1999.
Egan CT, Herrick-Davis K, Miller K, Glennon RA, and Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 136: 409–414, 1998.[CrossRef][Medline]
Elkashef AM, Issa F, and Wyatt RJ. The biochemical basis of schizophrenia. In: Contemporary Issues in the Treatment of Schizophrenia, edited by Shriqui CL and Nasrallah HA. Washington, DC: American Psychiatric Press, 1995, p. 3–41.
Ferguson SM, Rayport M, Gardner R, Kass W, Weiner H, and Reiser MF. Similarities in mental content of psychotic states, spontaneous seizures, dreams, and responses to electrical brain stimulation in patients with temporal lobe epilepsy. Psychosom Med 31: 479–498, 1969.
Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J, Casado V, Lledo P, Zoli M, Lluis C, and Fuxe K. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23: S50–S59, 2000.[CrossRef][ISI][Medline]
Frederick JA and Meador-Woodruff JH. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain. Schizophr Res 38: 7–12, 1999.[CrossRef][ISI][Medline]
Frey U, Huang YY, and Kandel ER. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260: 1661–1664, 1993.
Gasbarri A, Campana E, Pacitti C, Hajdu F, and Tombol T. Organization of the projections from the ventral tegmental area of Tsai to the hippocampal formation in the rat. J Hirnforsch 32: 429–437, 1991.[ISI][Medline]
Gasbarri A, Campana E, Pacitti F, and Pacitti C. Projections of the Tsai tegmental ventral area to the hippocampus: a study of the rat using the Fink-Heimer technic. Boll Soc Ital Biol Sper 65: 639–645, 1989.[Medline]
Gasbarri A, Packard MG, Sulli A, Pacitti C, Innocenzi R, and Perciavalle V. The projections of the retrorubral field A8 to the hippocampal formation in the rat. Exp Brain Res 112: 244–252, 1996.[ISI][Medline]
George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O’Dowd BF. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128–26135, 2000.
Gerard C, Martres MP, Lefevre K, Miquel MC, Verge D, Lanfumey L, Doucet E, Hamon M, and el Mestikawy S. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 746: 207–219, 1997.[CrossRef][ISI][Medline]
Gloor P. The Temporal Lobe and Limbic System. Oxford: Oxford, 1997.
Gonzalez AM, Pascual J, Meana JJ, Barturen F, del Arco C, Pazos A, and Garcia-Sevilla JA. Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem 63: 256–265, 1994.[ISI][Medline]
Grahn RE, Will MJ, Hammack SE, Maswood S, McQueen MB, Watkins LR, and Maier SF. Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res 826: 35–43, 1999.[CrossRef][ISI][Medline]
Gray JA. Integrating schizophrenia. Schizophr Bull 24: 249–266, 1998.
Gurvits IG, Koenigsberg HW, and Siever LJ. Neurotransmitter dysfunction in patients with borderline personality disorder. Psychiatr Clin North Am 23: 27–40, 2000.[CrossRef][ISI][Medline]
Hebert TE and Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol 76: 1–11, 1998.[CrossRef][ISI][Medline]
Hedlund PB, Carson MJ, Sutcliffe JG, and Thomas EA. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol 58: 1807–1813, 1999.[CrossRef][ISI][Medline]
Hessler NA, Shirke AM, and Malinow R. The probability of transmitter release at a mammalian central synapse. Nature 366: 569–572, 1993.[CrossRef][Medline]
Holmberg M, Fagerholm V, and Scheinin M. Regional distribution of alpha(2C)-adrenoceptors in brain and spinal cord of control mice and transgenic mice overexpressing the alpha(2C)-subtype: an autoradiographic study with [(3)H]RX821002 and [(3)H]rauwolscine. Neuroscience 117: 875–898, 2003.[CrossRef][ISI][Medline]
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, and Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157–203, 1994.[Abstract]
Huang YY and Kandel ER. D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci USA 92: 2446–2450, 1995.
Hyde TM and Weinberger DR. Seizures and schizophrenia. Schizophr Bull 23: 611–622, 1997.[ISI][Medline]
Iqbal N and HM. ole of serotonin in schizophrenia. Eur Neuropsychopharmacol 5(suppl): 11–23, 1995.[Medline]
Jackson D and Mohell N. A review of the pharmacology of new antipsychotic drugs. In: CNS Neurotransmitters and Neuromodulators: Dopamine, edited by Stone T. Boca Raton, FL: CRS Press, 1996, p. 185–200.
Kan R, Mori Y, Suzuki S, Ono T, Takahashi Y, and Kumashiro H. A case of temporal lobe astrocytoma associated with epileptic seizures and schizophrenia-like psychosis. Jpn J Psychiatry Neurol 43: 97–103, 1989.[Medline]
Kapur S and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476, 1996.
Katsuki H, Izumi Y, and Zorumski CF. Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. J Neurophysiol 77: 3013–3020, 1997.
Kavoussi R, Armstead P, Coccaro E, Ahlenius S, Hillegaart V, Wijkstrom A, Le Monnier de Gouville AC, Lawson K, Thiry C, and Cavero I. The neurobiology of impulsive aggression. Psychiatr Clin North Am 20: 395–403, 1997.[CrossRef][ISI][Medline]
Kebabian J and Neumeyer J, eds. The RBI Handbook of Receptor Classification. Natick, MA: RBI, 1994.
Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S, Hamon M, and Verge D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J Comp Neurol 365: 289–305, 1996.[CrossRef][ISI][Medline]
Kitchigina V, Vankov A, Harley C, and Sara SJ. Novelty-elicited, noradrenaline-dependent enhancement of excitability in the dentate gyrus. Eur J Neurosci 9: 41–47, 1997.[CrossRef][ISI][Medline]
Larkman PM and Kelly JS. Modulation of IH by 5-HT in neonatal rat motoneurones in vitro: mediation through a phosphorylation independent action of cAMP. Neuropharmacology 36: 721–733, 1997.[CrossRef][ISI][Medline]
Laruelle M and Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13: 358–371, 1999.
